Saúde
A recent Brazilian court ruling ordered SUS to provide Mounjaro to a patient. Here's what that decision means for health insurance coverage and GLP-1 access in Brazil.
Brazilian health authorities are cracking down on illegal imports of tirzepatide from Paraguay. Here's what patients need to know about the dangers and legal consequences of buying this medication through contraband channels.
Brazil's ANVISA set clear rules for app-based medication delivery, closing a regulatory gap. Here's what changes for patients using GLP-1 medications and the platforms serving them.
Fake Ozempic pens are appearing in more countries, putting patients at serious risk. Learn how to verify your pen's authenticity and what steps to take if you suspect you bought a counterfeit.
Brazil's ANVISA has warned about risks of mixing energy drinks with GLP-1 weight loss medications. Here's what patients need to know about the real dangers for their heart, blood sugar, and treatment effectiveness.
Wondering if you can safely drink alcohol while using GLP-1 weight loss pens like Ozempic or Mounjaro? Here's what medical guidelines and specialists actually recommend.
Insurance companies often deny Ozempic for weight loss because it's FDA-approved for diabetes, not obesity. Here's what you need to know about coverage, appeals, and your options.
Weight regain after stopping GLP-1 medications is a documented physiological response, not a failure of willpower. Here's what research shows and how to prepare.
Discover when Brazilian health insurance plans are legally required to cover Ozempic or Mounjaro, how the ANS mandatory coverage list works, and what steps to take if your insurer denies your claim.
Wondering whether GLP-1 injection pens like Ozempic or Mounjaro can cause hair loss? Here's what the science says about telogen effluvium, nutritional gaps, and practical steps to protect your hair during treatment.
